The complement cascade, once considered a peripheral arm of innate immunity, has emerged as the central pathological driver in a growing constellation of diseases. From atypical hemolytic uremic syndrome to paroxysmal nocturnal hemoglobinuria, dysregulation of these ancient proteolytic pathways produces clinically devastating consequences. What was once a diagnostic mystery is now resolvable through sophisticated functional and genetic profiling.

Precision complement medicine has matured rapidly over the past decade. We can now characterize pathway involvement with remarkable granularity, distinguishing classical from alternative pathway dysregulation, identifying causative variants in regulatory proteins, and quantifying terminal complex formation in real time. This molecular precision translates directly into therapeutic decisions that were unimaginable a generation ago.

The therapeutic implications are profound. Monoclonal antibodies targeting C5, factor B inhibitors, factor D blockers, and C3-targeted agents now offer pathway-specific intervention. Yet appropriate patient selection remains the defining challenge. A patient with complement-mediated thrombotic microangiopathy responds dramatically to eculizumab; another with morphologically similar disease but distinct pathway involvement may not. This article examines how comprehensive complement profiling guides both diagnosis and targeted intervention across the spectrum of complement-mediated conditions, transforming a previously empirical therapeutic landscape into one driven by molecular phenotyping.

Comprehensive complement assessment requires evaluation across three converging pathways: classical, alternative, and lectin. Each is initiated by distinct molecular triggers but ultimately converges on C3 activation and terminal complex assembly. Discriminating which pathway drives a given disease state demands a coordinated panel of functional assays, protein quantification, and increasingly, genetic sequencing.

Functional testing typically begins with CH50 and AH50 assays, which assess classical and alternative pathway integrity respectively. Reduced CH50 with preserved AH50 suggests classical pathway consumption or C1, C2, or C4 deficiency. Conversely, isolated AH50 reduction implicates factor B, factor D, or properdin abnormalities. The Wieslab ELISA-based functional assay extends this analysis by quantifying terminal complex formation through each pathway independently.

Quantitative measurement of individual components provides the next analytical layer. Low C3 with normal C4 strongly suggests alternative pathway activation, characteristic of C3 glomerulopathy and aHUS. Concurrent C3 and C4 depression points toward classical pathway consumption, as seen in lupus nephritis. Soluble C5b-9 measurement offers direct evidence of terminal pathway activation and serves as a sensitive biomarker for ongoing complement-mediated injury.

Genetic analysis has become indispensable, particularly for suspected complementopathies. Next-generation sequencing panels routinely interrogate CFH, CFI, CFB, C3, MCP/CD46, THBD, and DGKE, alongside copy number analysis for CFHR1-CFHR5 rearrangements. Anti-factor H autoantibodies, frequently associated with CFHR1 deletions, require parallel serological testing.

Integration of these data streams produces a comprehensive complement phenotype. The clinical utility extends beyond diagnosis: pathway-specific findings predict treatment response, guide monitoring intensity, and inform family screening when germline variants are identified.

Takeaway

Complement profiling is not a single test but a coordinated diagnostic strategy. Functional, quantitative, and genetic data must converge before molecular phenotype can guide therapy.

Each complement-mediated disease carries a recognizable molecular fingerprint, though heterogeneity within syndromes remains substantial. Atypical hemolytic uremic syndrome exemplifies this principle: roughly 60 percent of patients harbor identifiable genetic variants in complement regulators, most commonly CFH, followed by MCP, CFI, and C3 gain-of-function mutations. The remaining cases may involve autoantibodies or as-yet-uncharacterized variants, yet share the unifying feature of uncontrolled alternative pathway activation at endothelial surfaces.

C3 glomerulopathy presents a distinct profile characterized by persistent C3 consumption with normal C4 and frequent presence of C3 nephritic factors, autoantibodies that stabilize the alternative pathway C3 convertase. Subclassification into dense deposit disease and C3 glomerulonephritis requires electron microscopy, but complement profiling differentiates these from immune-complex glomerulonephritides where classical pathway involvement predominates.

Paroxysmal nocturnal hemoglobinuria diverges mechanistically. Rather than dysregulated activation, PNH reflects deficiency of GPI-anchored complement regulators CD55 and CD59 on hematopoietic cells due to acquired PIGA mutations. Flow cytometric quantification of GPI-anchor deficient cells across granulocyte, monocyte, and erythrocyte lineages defines clone size and predicts hemolytic burden.

Age-related macular degeneration represents a more nuanced relationship. Common CFH Y402H polymorphisms and CFI variants increase risk through subtle alternative pathway dysregulation, distinct from the dramatic activation seen in aHUS. This polygenic complement vulnerability translates into chronic, low-grade complement-mediated tissue injury rather than acute thrombotic microangiopathy.

Myasthenia gravis introduces yet another pattern: classical pathway activation at the neuromuscular junction driven by acetylcholine receptor autoantibodies. Terminal complex formation directly damages postsynaptic membranes, making C5 inhibition therapeutically rational specifically in antibody-positive generalized disease.

Takeaway

Similar clinical phenotypes often mask divergent complement mechanisms. Molecular signatures reveal which pathway is driving disease, and therefore which intervention will work.

The therapeutic armamentarium has expanded from a single C5 inhibitor to a sophisticated portfolio of pathway-specific agents. Eculizumab, the prototype humanized anti-C5 monoclonal antibody, blocks terminal pathway activation and prevents C5a generation and C5b-9 assembly. Its efficacy in aHUS, PNH, and generalized myasthenia gravis established the proof of concept for complement-targeted therapeutics, though its weight-based dosing schedule and meningococcal infection risk require structured monitoring protocols.

Ravulizumab, an engineered variant with extended half-life through Fc neonatal receptor binding optimization, permits eight-weekly dosing while maintaining equivalent C5 blockade. Patient selection between eculizumab and ravulizumab now hinges primarily on dosing convenience, clone characteristics in PNH, and rare C5 polymorphisms that affect ravulizumab binding, particularly the R885H variant prevalent in Japanese populations.

Pegcetacoplan introduces a fundamentally different strategy by targeting C3, the central convergence node. In PNH, proximal C3 inhibition addresses both intravascular hemolysis and the extravascular hemolysis that emerges as a limiting toxicity of pure C5 blockade. This proximal-versus-terminal distinction defines an important new axis of treatment selection.

Factor B and factor D inhibitors, including iptacopan and danicopan, offer alternative pathway-selective inhibition with oral bioavailability. These agents preserve classical pathway function, theoretically reducing infection risk while addressing diseases driven specifically by alternative pathway dysregulation, such as C3 glomerulopathy and PNH.

Patient selection now integrates pathway involvement, anticipated treatment duration, infection risk profile, and pharmacological convenience. Pretreatment vaccination against encapsulated organisms remains universal, but ongoing prophylaxis decisions increasingly reflect the specific complement node being inhibited.

Takeaway

Choosing a complement inhibitor is no longer a binary decision. It requires mapping the disease mechanism onto a layered pharmacological hierarchy, from proximal to terminal pathway blockade.

Complement-mediated diseases have transitioned from poorly understood syndromes to molecularly tractable conditions within a remarkably compressed timeframe. The convergence of functional assays, genetic sequencing, and pathway-specific therapeutics has created a genuinely precision-based clinical framework.

Yet challenges persist. Genotype-phenotype correlations remain imperfect, treatment response prediction is still probabilistic rather than deterministic, and the cost of complement inhibitors imposes practical constraints on indefinite therapy. Emerging biomarkers, including ex vivo complement activation assays and tissue-specific deposition imaging, may refine these decisions further.

The broader lesson extends beyond complement itself. When a pathological cascade is anatomically and biochemically defined, targeted intervention becomes possible at multiple nodes. The discipline required is matching molecular phenotype to therapeutic mechanism with rigor and humility, acknowledging that pathway-level understanding does not eliminate biological complexity but renders it navigable.